Leishmaniasis chemotherapy--challenges and opportunities
- PMID: 21933306
- DOI: 10.1111/j.1469-0691.2011.03630.x
Leishmaniasis chemotherapy--challenges and opportunities
Abstract
Although there have been significant advances in the treatment of visceral leishmaniasis (VL), there remain challenges to ensure that treatments effective in India are also effective in other regions of the world and to identify treatment for post kala-azar dermal leishmaniasis as well as the opportunity to develop a safe oral short-course treatment. At the same time, there have been few advances for the treatment of simple or complex forms of cutaneous leishmaniasis (CL), other than topical paromomycin formulations. The main challenge for CL is to ensure that this disease is on the research and development agenda, so that new drugs are evaluated or compounds are screened in appropriate models, and that the standardization of quality of clinical trials is guaranteed. Problems also remain in the treatment of HIV/leishmaniasis co-infected patients. We are some way from having the ideal treatments for VL and CL and drug research and development for these diseases must remain focused.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.
Similar articles
-
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12. Trop Med Int Health. 2012. PMID: 22882665
-
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.J Assoc Physicians India. 2003 Jul;51:686-90. J Assoc Physicians India. 2003. PMID: 14621038 Review.
-
Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.Infection. 2008 Mar;36(2):184-6. doi: 10.1007/s15010-007-6279-5. Epub 2008 Mar 10. Infection. 2008. PMID: 18327683 No abstract available.
-
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0. Infect Dis Poverty. 2018. PMID: 30099967 Free PMC article.
-
Treatment of leishmaniasis with miltefosine: 2008 status.Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209. Expert Opin Drug Metab Toxicol. 2008. PMID: 18721114 Review.
Cited by
-
In Vitro Susceptibility of Leishmania infantum to Artemisinin Derivatives and Selected Trioxolanes.Antimicrob Agents Chemother. 2015 Aug;59(8):5032-5. doi: 10.1128/AAC.00298-15. Epub 2015 May 26. Antimicrob Agents Chemother. 2015. PMID: 26014947 Free PMC article.
-
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Antimicrob Agents Chemother. 2012 Jul;56(7):3864-72. doi: 10.1128/AAC.00292-12. Epub 2012 May 14. Antimicrob Agents Chemother. 2012. PMID: 22585212 Free PMC article. Clinical Trial.
-
Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics.J Biol Chem. 2019 Apr 5;294(14):5365-5385. doi: 10.1074/jbc.REV118.002956. Epub 2019 Jan 22. J Biol Chem. 2019. PMID: 30670594 Free PMC article. Review.
-
Access and utilization of host-derived iron by Leishmania parasites.J Biochem. 2023 Dec 20;175(1):17-24. doi: 10.1093/jb/mvad082. J Biochem. 2023. PMID: 37830941 Free PMC article. Review.
-
Insilico analysis of hypothetical proteins unveils putative metabolic pathways and essential genes in Leishmania donovani.Front Genet. 2014 Aug 26;5:291. doi: 10.3389/fgene.2014.00291. eCollection 2014. Front Genet. 2014. PMID: 25206363 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources